CD274 and non-small cell lung carcinoma: Thus, ICIs are now widely used as first line monotherapy in patients with advanced stage NSCLC and >50% membranous PD-L1 positive tumor cells and in combination with chemotherapy irrespective of PD-L1 expression (2).